Harvard Medical School Center for Biomedical Informatics, 10 Shattuck Street, Boston, Massachusetts 02115, USA.
Nat Rev Drug Discov. 2012 Feb 1;11(2):89-90. doi: 10.1038/nrd3659.
Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to have narrower implications than suggested by initial studies.
全基因组筛查有望通过识别和利用基因组变异与药物反应之间的新关联来加速个体化医学的发展。然而，如果不注意最小化药物基因组关联的影响，而这些关联的影响比初步研究表明的要窄，那么这一目标可能会受到损害。
